Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic Small-Cell Lung Cancer: Results From the KEYNOTE-028 and KEYNOTE-158 Studies.
Journal of Thoracic Oncology(2020)
摘要
Pembrolizumab demonstrated durable antitumor activity in subset of patients with recurrent/metastatic SCLC who had ≥2 previous lines of therapy, regardless of PD-L1 expression. Pembrolizumab was well tolerated.
更多查看译文
关键词
Third-line therapy,Pembrolizumab,SCLC,Immunotherapy
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络